Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.41 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.37 |
| ▸ | ST6GAL1 | P15907 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828271 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9P2RY6P2RY2P2RY14 | |
| SCHEMBL15828240 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9P2RY6P2RY2P2RY14 | |
| SCHEMBL15828277 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9P2RY6P2RY2P2RY14 | |
| SCHEMBL15828236 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9P2RY6P2RY2P2RY14 | |
| SCHEMBL15588673 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9P2RY6P2RY2P2RY14 | |
| SCHEMBL15828274 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9P2RY6P2RY2P2RY14 | |
| SCHEMBL15828269 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9P2RY6P2RY2P2RY14 | |
| SCHEMBL15588460 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9P2RY6P2RY2P2RY14 | |
| SCHEMBL15828280 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9P2RY6P2RY2P2RY14 | |
| SCHEMBL15828242 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9P2RY6P2RY2P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9211300-B2 | 4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140178338-A1 | 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV | UNIVERSITE DE MONTPELLIER (FR) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178338-A1 | 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV | FBL, HNRNPLL, SLC28A1 | CYP3A4 1243/4885CYP2C9 3023/4885P2RY6 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.